Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i

Anna Simanenkova1,2, Oksana Fuks1, Natalya Timkina1,2

  • 1Institution of Endocrinology, Almazov National Medical Research Centre, 197341 Saint-Petersburg, Russia.

Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) show neuroprotective effects in diabetic rats. GLP-1RAs demonstrated a more pronounced effect on reducing infarct volume and microglial activation.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (DM) is associated with acute and chronic brain damage.
  • Investigating neuroprotective agents is crucial for managing diabetic complications.
  • Glucose-lowering drugs, specifically GLP-1RAs and SGLT-2i, are candidates for neuroprotection.

Purpose of the Study:

  • To directly compare the neuroprotective effects of GLP-1RAs (liraglutide, dulaglutide) and SGLT-2i (canagliflozin).
  • To evaluate these effects in type 2 diabetic rats with and without induced stroke.
  • To assess both acute and chronic brain damage models.

Main Methods:

  • Type 2 diabetes mellitus was induced in rats using a high-fat diet and nicotinamide+streptozotocin.
  • Animals were treated with liraglutide, dulaglutide, or canagliflozin for 8 weeks.
  • Middle cerebral artery occlusion was performed to model stroke; neurological deficit, neuroglial markers, and brain necrosis were assessed.

Main Results:

  • All tested drugs reduced brain damage volume compared to untreated diabetic rats.
  • GLP-1RAs (liraglutide, dulaglutide) showed a more pronounced reduction in infarct volume than SGLT-2i (canagliflozin).
  • GLP-1RAs, particularly dulaglutide, were more effective in reducing microglial activation and neurofilament light chains.

Conclusions:

  • Both GLP-1RAs and SGLT-2i possess significant neuroprotective properties against acute and chronic brain damage in type 2 diabetes.
  • GLP-1RAs appear to offer a more pronounced infarct-limiting effect.
  • Neuroprotection is achieved through direct neuronal survival influence, with GLP-1RAs also modulating microglial activity.